BIOMAT Database Logo BIOMAT Database Logo

Human Philadelphia chromosome-positive chronic myeloid leukemia: a potential model for antisense therapy. 1993

C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Section of Medicine, Institute of Cancer Research, Sutton, Surrey, England.

We have developed an in vivo model of human chronic myeloid leukemia (CML). A peripheral blood (PB) sample of Philadelphia (Ph) chromosome-positive CML cells in lymphoid blast crisis was transplanted intravenously (IV) into sublethally irradiated severe combined immunodeficient (SCID) mice, and this resulted in engraftment with systemic proliferation. Growth of leukemia was monitored by PB cell morphology and by flow cytometric analysis of murine PB cells labelled with an anti-human leukocyte antigen (HLA) monoclonal antibody. Human cells were first detected in the PB at 4 weeks and comprised a mean of 57% of the total nucleated cells in the PB of these mice by 15 weeks. The Ph chromosome was retained and the population has been successfully passaged. BCR/ABL fusion gene expression was detected in a subsequent passage. Experiments are underway to use this in vivo model to assess the antileukemic activity of BCR/ABL antisense oligonucleotides.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D005453 Fluorescence The property of emitting radiation while being irradiated. The radiation emitted is usually of longer wavelength than that incident or absorbed, e.g., a substance can be irradiated with invisible radiation and emit visible light. X-ray fluorescence is used in diagnosis.
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes

Related Publications

C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Philadelphia chromosome-negative, lysozyme-positive chronic myeloid leukemia.
January 1973, Haematologia,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
[Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].
July 2019, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Molecular diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia.
January 1991, Haematologica,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Plasmablastic crisis of Philadelphia chromosome-positive chronic myeloid leukemia.
June 2010, Annals of hematology,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
December 2010, Expert opinion on pharmacotherapy,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
January 2016, Indian journal of pharmacology,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL).
December 2002, Internal medicine (Tokyo, Japan),
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Philadelphia chromosome positive acute myeloid leukemia or de novo chronic myeloid leukemia-blast phase?
January 2013, Leukemia & lymphoma,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
January 2008, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
C De Lord, and R D Clutterbuck, and R L Powles, and T Min, and J C Titley, and J L Millar
Translocation 3;21 in Philadelphia chromosome positive chronic myeloid leukemia at diagnosis.
June 1989, Cancer genetics and cytogenetics,
Copied contents to your clipboard!